scholarly journals ROLE OF MOMETASONE FUROATE NASAL SPRAY IN ADENOID HYPERTROPHY IN CHILDREN WITH OSA

2016 ◽  
Vol 5 (93) ◽  
pp. 6891-6896
Author(s):  
Praveen Prasannan ◽  
Sadarudheen Ahmed Mohammed Islah
Keyword(s):  
Nasal Spray ◽  
Mometasone Furoate ◽  
Adenoid Hypertrophy

scholarly journals Role of mometasone furoate nasal spray in children with adenoid hypertrophy: impact on life style changes

2020 ◽  
Vol 6 (9) ◽  
pp. 1709
Author(s):  
Venkatesha B. K. ◽  
Ravi Shekhar
Keyword(s):  
Nasal Obstruction ◽  
Nasal Spray ◽  
Statistical Tests ◽  
Nasal Congestion ◽  
Sleep Apnea Syndrome ◽  
Mometasone Furoate ◽  
Nasal Discharge ◽  
Adenoid Hypertrophy ◽  
Obstructive Sleep ◽  
Life Style Changes

<p class="abstract"><strong>Background:</strong> Adenoid hypertrophy (AH) is a common cause of upper airway obstruction and obstructive sleep apnea syndrome (OSAS) in children having major impact on child’s growth and development. Symptoms like nasal congestion, mouth breathing, nasal discharge, snoring, day time sleepiness, hyponasal voice, ear popping, and craniofacial abnormalities are observed. Adenoidectomy is considered the treatment of choice for symptomatic children. Co-existing medical illnesses and choice of surgical treatment is governed by the paediatricians and apprehensive parents. Need for conservative treatments in alleviating symptoms have been tried. Topical, intranasal administered, steroid preparations have been proven effective in the literature.</p><p class="abstract"><strong>Methods:</strong> In this prospective study, 35 symptomatic children (3-12 years) with adenoid hypertrophy were included. Each of the symptoms was scored from 0 (absent) to 4 (severe) over Visual Analogue Scale (VAS). Nasal obstruction index was calculated. Results of mometasone furoate nasal spray 100 microgram/day used once daily at the interval of 8 weeks and 12 weeks were analysed using statistical tests.  </p><p class="abstract"><strong>Results:</strong> A statistically significant reduction in nasal obstruction index and other symptoms were noted at the end of third month follow up.</p><p class="abstract"><strong>Conclusions:</strong> Mometasone furoate nasal spray caused improvements in outcomes of nasal obstruction, snoring, total nasal symptoms, ear symptoms and overall quality of life.</p>

Effect of topical mometasone furoate on adenoidal lymphoid tissue: a light microscopic study

2019 ◽  
Vol 133 (2) ◽  
pp. 106-109 ◽  
Author(s):  
M R Ahmed ◽  
A S Abou-Halawa ◽  
I H Ibrahim ◽  
R F Zittoon ◽  
E F Y Makary
Keyword(s):  
Nasal Spray ◽  
Lymphoid Tissue ◽  
Topical Steroid ◽  
Upper Airway ◽  
Mometasone Furoate ◽  
Control Group ◽  
Adenoid Hypertrophy ◽  
Nasal Steroids ◽  
Grade 3 ◽  
Adenoidal Tissue

AbstractBackgroundAdenoid hypertrophy is a common cause of upper airway obstruction, and adenoidectomy is one of the most frequently performed operations in children. Topical nasal steroids can act directly on nasopharyngeal lymphoid tissue to decrease its reactive inflammatory changes and potentially reduce its size.ObjectiveTo study the light microscopic changes in adenoidal lymphoid tissue after one month of topical steroid use.MethodsTwenty-six children with adenoid hypertrophy grade 3 scheduled for adenoidectomy were randomly divided into two equal groups: one group received mometasone furoate aqueous nasal spray (Nasonex) 100 mcg/day for four weeks, and a control group received nasal normal saline 0.9 per cent for four weeks. The removed adenoids were examined histopathologically.ResultsAdenoidal tissue from the mometasone group had less reactive germinal centres and less spongiosis compared to the control group. The latter showed proliferating, reactive, variable sized and shaped lymphoid follicles, with congested blood vessels in the interfollicular areas.ConclusionThe use of intranasal mometasone furoate aqueous nasal spray (Nasonex) for one month reduced adenoidal tissue reactive cellular changes and its vascularity. This is, however, a pilot study; a longer treatment period is needed to assess the effect of treatment on adenoidal size.

scholarly journals The role of bacteriotherapy in the restoration of the nasal mucosa in patients with chronic rhinosinusitis

2021 ◽  
pp. 62-67
Author(s):  
Alexander N. Naumenko ◽  
Ahmad Abdelrazzaq Moh’dabdel razzaq ◽  
Margaryta R. Amirkhanova
Keyword(s):  
Topical Corticosteroid ◽  
Chronic Rhinosinusitis ◽  
Nasal Spray ◽  
Nasal Mucosa ◽  
Mometasone Furoate ◽  
Streptococcus Salivarius ◽  
Saline Irrigation ◽  
Significant Difference ◽  
Snot 22

Topicality: Chronic rhinosinusitis is an polyetiological disease with shch basic complaints as nasal obstruction, nasal discharge, headache or facial pain and reduction of smell. The SNOT-22 questionnaire is widely used to detail patient complaints in various fields. Chronic rhinosinusitis is most often divided into chronic rhinosinusitis with polyps and without nasal polyps. Given the large number of phenotypes and endotypes of the disease, it is important to study further the mechanisms of pathogenesis and selec- tion of individualized treatment. Aim: to determine the role of topical application of Streptococcus salivarius 24SMBc and Streptococcus orals 89a in the form of nasal spray in improving the condition of the nasal mucosa in chronic rhinosinusitis and reducing the recurrence rate. Materials and methods: The study was conducted at the Department of Otolaryngology of National Medical University on the basis of KNP "Oleksandrivs’ka Clinical Hospital of Kyiv". It was attended by 82 patients (38 women and 44 men) aged 18 to 60 years, who were randomly divided into two groups. The 1st group (main, 43 patients) received treatment: irrigation therapy with isotonic saline, topical corticosteroid mometasone furoate in combination with a nasal spray, which contains autochthonous saprophytes (AC) – Streptococcus salivarius 89SMBc and Streptococcus orals 89a nasal mucus. The 2nd group (control, 39 patients) received nasal saline irrigation therapy, topical corticosteroid mometasone furoate in combination with topical antibiotic framicetin sulfate. Assessment was performed according to the VAS scale, SNOT-22 questionnaire (before treatment, on the 10th day of treatment and one month after the end of therapy) and determining the frequency of relapses in patients of both groups. Results: According to the obtained results, the indicators of patients of both groups before treatment and on the 10th day had no statistically significant difference (p>0.05). However a month later patients in the main group had better results (p<0.05) on the scale of VAS and the SNOT-22 questionnaire. So, topical use of Streptococcus salivarius 24SMBc and Streptococcus orals 89a as a nasal spray is effective and can be recommended for the treatment of patients with chronic rhinosinusitis in the acute stage.

scholarly journals The role of budesonide and mometasone furoate on the nasal and sinus symptoms in allergic rhinosinuitis: a randomized study

2019 ◽  
Vol 6 (1) ◽  
pp. 15
Author(s):  
Sriram Govindaraj ◽  
Ganeshbala Arivazhagan ◽  
Jayendiran Subramani ◽  
Jinu Vadakkanethu Iype ◽  
Ilango Chakkravarthy
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Spray ◽  
Work Performance ◽  
Randomized Study ◽  
Nasal Symptom ◽  
Mometasone Furoate ◽  
Budesonide Group ◽  
Group B ◽  
The Individual

<p class="abstract"><strong>Background:</strong> Allergic rhinosinuitis is one of the common clinical problems that otorhinolaryngologist faces daily. Sinusitis symptoms like headache, facial pain and eyelid oedema are frequent in patients with allergic rhinitis, which in turn will affect the cognitive function, productivity and quality of life which impair the efficiency of the individual work performance. It may result in a prescription for antibiotics but the role of antibiotics is debated. Anti-inflammatory drugs such as intranasal steroids play a major role in reducing the symptoms of allergic rhinitis. We plan to compare the efficacy of budesonide nasal spray with mometasone furoate nasal spray in reducing the nasal and sinus symptoms of allergic rhinosinusitis.</p><p class="abstract"><strong>Methods:</strong> 146 patients of allergic rhinitis with sinusitis symptoms were randomly divided into 2 groups as Group A (n=70) received 256 μg budesonide nasal spray of once daily and Group B (n=76) received 200 μg of mometasone furoate nasal spray daily. The patients were assessed by sino-nasal outcome test (SNOT) score and total nasal symptom score (TNSS) at 2, 6 and 12 weeks interval.  </p><p class="abstract"><strong>Results:</strong> There is significant reduction in both the groups, in respect to the SNOT and TNSS scores. We also observed significant improvement in the SNOT score in the budesonide group when compared with the mometasone furoate group by 6weeks which continued till the 12 weeks (p=0.001).</p><p class="abstract"><strong>Conclusions:</strong> Budesonide nasal spray is more effective than mometasone furoate spray in managing both sinus and nasal symptoms in allergic rhinitis.</p>

Role of mometasone furoate aqueous nasal spray for management of adenoidal hypertrophy in children

2014 ◽  
Vol 128 (12) ◽  
pp. 1060-1066 ◽  
Author(s):  
R Bhargava ◽  
A Chakravarti
Keyword(s):  
Quality Of Life ◽  
Nasal Spray ◽  
Mometasone Furoate ◽  
Controlled Study ◽  
Control Group ◽  
Score Change ◽  
Double Blind ◽  
Adenoidal Hypertrophy

AbstractObjectives:To study the role of mometasone furoate aqueous nasal spray for the management of adenoidal hypertrophy in children with more than 50 per cent obstruction, and to assess its impact on change in quality of life.Methods:A prospective, randomised, double-blind, interventional placebo-controlled study was conducted. A total of 100 children aged 2–12 years completed treatment and follow up. The symptoms and degree of obstruction were evaluated by nasopharyngoscopy conducted pre-treatment and 24 weeks post-treatment. Subjects received mometasone furoate nasal spray at a daily dose of 200 µg for 8 weeks, followed by a dose of 200 µg on alternate days for 16 weeks. Results were compared with those of a matched control group who were given saline nasal spray.Results:With mometasone treatment, there was an 89.8 per cent reduction in clinical symptom score, and the degree of obstruction dropped from 87 to 72 per cent (p < 0.0001). A statistically significant change in quality of life scores was seen in patients treated with the mometasone nasal spray (score change of 37.47) as compared with those given saline nasal spray (score change of 11.25) (p = 0.0001).Conclusion:Mometasone nasal spray appears to be effective in treating children with obstructive adenoids.

scholarly journals Role of intranasal fluticasone furoate spray in modifying quality of life of children with adenoid hypertrophy

2020 ◽  
Vol 24 (1) ◽  
pp. 22-28
Author(s):  
Md Mazharul Islam ◽  
AKM Rezaul Karim ◽  
Md Ahsanul Habib ◽  
Nafisa Zaman ◽  
Md Tanvir Hasan
Keyword(s):  
Nasal Spray ◽  
Prospective Observational Study ◽  
Clinical Symptoms ◽  
Adenoid Hypertrophy ◽  
Fluticasone Furoate ◽  
College Hospital ◽  
Medical College ◽  
Pediatric Age Group

Introduction: Symptoms of adenoid hypertrophy is commonly seen among the pediatric age group. Since the surgical approach for this on immunity is controversial, the study was planned out to appraise the outcome of intranasal Fluticasone Furoate spray use. Objective:To find out the efficacy of Fluticasone Furoate nasal spray in reducing clinical symptoms due to enlarged adenoid. Methods: The prospective observational study was conducted in the Rangpur Medical College Hospital between April 2017 to August 2017 among 64 patients aged 4-15 years. Improvement on clinical symptoms was assessed by the structured OSA-18 questionnaire. Results: At the end of 4 weeks, statistically significant improvement (p < 0.001) was observed in nearly all the domains of among the 64 participants. The average total score showed improvement from 60.95 to 46.37. Conclusion:The use of fluticasone furoate nasal spray considered to be useful in reducing clinical symptoms of adenoid hypertrophy among children. Bangladesh J Otorhinolaryngol; April 2018; 24(1): 22-28

scholarly journals Role of mometasone furoate nasal spray versus saline nasal spray in treatment of adenoid hypertrophy: a prospective, randomized study

2020 ◽  
Vol 6 (10) ◽  
pp. 1841
Author(s):  
Rabia Monga ◽  
Sanjeev Bhagat ◽  
Vishal Sharma ◽  
Dimple Sahni ◽  
Harjinder Singh ◽  
...  
Keyword(s):  
Nasal Obstruction ◽  
Nasal Spray ◽  
Clinical Symptoms ◽  
Randomized Study ◽  
Mometasone Furoate ◽  
Nasal Endoscopy ◽  
Prospective Randomized Study ◽  
Common Symptom ◽  
Adenoid Hypertrophy ◽  
Obstructive Sleep

<p class="abstract"><strong>Background: </strong>Adenoid hypertrophy is a common disorder in the paediatric population, presenting with multiple signs and symptoms ranging from nasal obstruction to obstructive sleep apnoea. Most common symptom is usually nasal airway obstruction. This prospective, randomized study aims to evaluate the efficacy of mometasone furoate spray in reducing size and clinical symptoms in patients with adenoid hypertrophy compared to saline spray.</p><p class="abstract"><strong>Methods:</strong> 60 patients in the age group of 3-11 years were enrolled in the study. Five symptoms were included that were hypo nasal speech, snoring, night cough, open mouth breathing and nasal obstruction which were scored as never=0, mild (sometimes)=1, moderate (less than 50% of times)=2, and severe (constant)=3. Diagnosis of adenoid hypertrophy was made on basis of nasal endoscopy.</p><p class="abstract"><strong>Results:</strong> Significant improvement was seen in individual as well as overall symptom score in group A as compared to group B after 8 weeks of treatment (p&lt;0.001). There was significant improvement in mean adenoid grade as per nasal endoscopy at 8 weeks post therapy (p&lt;0.001) which was not seen after 4 weeks of therapy.</p><p class="abstract"><strong>Conclusion:</strong> Intranasal steroid sprays have good role in decreasing the symptoms of adenoid hypertrophy and has reduced number of adenoidectomies required. The long-term effects as well as optimal duration of therapy is still controversial and needs to be studied further.</p>

Sign in / Sign up

Export Citation Format

Share Document